These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19249618)

  • 1. The Montreal Protocol: getting over the finishing line?
    Woodcock A
    Lancet; 2009 Feb; 373(9665):705-6. PubMed ID: 19249618
    [No Abstract]   [Full Text] [Related]  

  • 2. The president speaks: prevention is best: lessons from protecting the ozone layer.
    Woodcock A
    Thorax; 2012 Dec; 67(12):1028-31. PubMed ID: 23019254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
    DeCanio SJ; Norman CS
    J Environ Manage; 2007 Oct; 85(1):1-8. PubMed ID: 16982135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ozone layer and metered dose inhalers.
    Boulet LP
    Can Respir J; 1998; 5(3):176-9. PubMed ID: 9707462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growing ozone hole "hangover".
    Christen K
    Environ Sci Technol; 2005 Jun; 39(12):255A. PubMed ID: 16047761
    [No Abstract]   [Full Text] [Related]  

  • 6. CFC phaseouts: an update on the fate of the earth.
    Health Facil Manage; 1995 Mar; 8(3):112. PubMed ID: 10140778
    [No Abstract]   [Full Text] [Related]  

  • 7. The Montreal Protocol and essential use exemptions.
    D'Souza S
    J Aerosol Med; 1995; 8 Suppl 1():S13-7. PubMed ID: 10150490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hole truth.
    Solomon S
    Nature; 2004 Jan; 427(6972):289-91. PubMed ID: 14737143
    [No Abstract]   [Full Text] [Related]  

  • 9. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(63):17167-92. PubMed ID: 15806739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic insights aid the search for CFC substitutes: risk assessment of HCFC-123 as an example.
    Jarabek AM; Fisher JW; Rubenstein R; Lipscomb JC; Williams RJ; Vinegar A; McDougal JN
    Risk Anal; 1994 Jun; 14(3):231-50. PubMed ID: 8029495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new beginning: making way for CFC-free inhalers.
    Weller T
    Community Nurse; 1998 Nov; 4(10):23-4. PubMed ID: 10326377
    [No Abstract]   [Full Text] [Related]  

  • 13. Final rule on albuterol inhalers.
    FDA Consum; 2005; 39(4):3. PubMed ID: 16255065
    [No Abstract]   [Full Text] [Related]  

  • 14. Questions and answers about the environmental effects of ozone depletion and its interactions with climate change: 2010 assessment.
    Aucamp PJ; Björn LO; Lucas R
    Photochem Photobiol Sci; 2011 Feb; 10(2):301-16. PubMed ID: 21253671
    [No Abstract]   [Full Text] [Related]  

  • 15. The Montreal Protocol and metered dose inhalers.
    Navarro RP
    Med Interface; 1997 Apr; 10(4):135-6. PubMed ID: 10166800
    [No Abstract]   [Full Text] [Related]  

  • 16. Turning CFCs into salt.
    Environ Health Perspect; 1996 May; 104(5):468-9. PubMed ID: 8743429
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of the Montreal Protocol in protecting climate.
    Velders GJ; Andersen SO; Daniel JS; Fahey DW; McFarland M
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):4814-9. PubMed ID: 17360370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on "effects of cosmic rays on atmospheric chlorofluorocarbon dissociation and ozone depletion".
    Patra PK; Santhanam MS
    Phys Rev Lett; 2002 Nov; 89(21):219803; author reply 219804. PubMed ID: 12443457
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on "effects of cosmic rays on atmospheric chlorofluorocarbon dissociation and ozone depletion".
    Harris NR; Farman JC; Fahey DW
    Phys Rev Lett; 2002 Nov; 89(21):219801; author reply 219802. PubMed ID: 12443455
    [No Abstract]   [Full Text] [Related]  

  • 20. Aerosol drug delivery: developments in device design and clinical use.
    Smith J; Tiner R
    Lancet; 2011 Sep; 378(9795):982; author reply 982. PubMed ID: 21907859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.